ArticleScientific reports2021
Copper-67 radioimmunotheranostics for simultaneous immunotherapy and immuno-SPECT.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Alpha and Beta Emitters in Translational Nuclear Medicine: Clinical Advances, Challenges, and Future Direction.International journal of molecular sciences · 2026Review
- Radiocopper in BCMA-targeted immunotheranostics of myeloma.Theranostics · 2026Article
- NOTA and NODAGA Radionuclide Complexing Agents: Versatile Approaches for Advancements in Radiochemistry.Molecules (Basel, Switzerland) · 2025Review
- Production and Supply of Raw Materials for Radiometals used in Radionuclide Imaging and Therapy in Korea.Nuclear medicine and molecular imaging · 2025Review
- Radiocopper in Radiopharmacy and Medical Use: Current Status and Perspective.Journal of medicinal chemistry · 2025Review
- Monovalent and Divalent Designs of Copper Radiotheranostics Targeting Fibroblast Activation Protein in Cancer.Cancers · 2024Article
- Improved extraction efficiency of radioactive copper produced via accelerator neutrons method through phosphate buffer-enhanced column pre-treatment.Scientific reports · 2024Article
- Recent advances in copper homeostasis-involved tumor theranostics.Asian journal of pharmaceutical sciences · 2024Review
- Effectiveness of [European journal of nuclear medicine and molecular imaging · 2024Article
- The heterobivalent (SSTR2/albumin) radioligand [Theranostics · 2024Article
- Recent Advances inInternational journal of molecular sciences · 2023Review
- Article
- PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials.The oncologist · 2023Article
- Combined Cancer Immunotheranostic Nanomedicines: Delivery Technologies and Therapeutic Outcomes.ACS omega · 2023Review
- Current and potential roles of immuno-PET/-SPECT in CAR T-cell therapy.Frontiers in medicine · 2023Review
- Oncostatin M Receptor as a Therapeutic Target for Radioimmune Therapy in Synovial Sarcoma.Pharmaceuticals (Basel, Switzerland) · 2022Article
- A feasibility study of the therapeutic application of a mixture ofMedical physics · 2022Article
- Photoactivatable bis(thiosemicarbazone) derivatives for copper-64 radiotracer synthesis.Dalton transactions (Cambridge, England : 2003) · 2022Article
- Review
- PSMA-Targeting Imaging and Theranostic Agents-Current Status and Future Perspective.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Copper-67 (t
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.